Updates are available Correction dated 2023-02-27
Click to view Correction: https://doi.org/10.1007/s12288-023-01635-4
-
Authors
Chandrakala, S.
Toshniwal, Manoj
Halvawala, Mitesh
Padwal, Namita
Sidharthan, Neeraj
Malhotra, Pankaj
Prashantha, B.
Ballikar, Riya
Shah, Sandip
Apte, Shashikant
Viswanathan, T. Kasi
Ramanan, Vijay
Sharma, Akhilesh
Pawar, Dattatray
Pawar, Roshan
Shahavi, Vinayaka
-
Clinical Trials BETA
Clinical trials referenced in this document:
ctri/2019/04/018614 at Clinical Trials Registry Indiactri201904018614 at Clinical Trials Registry IndiaDocuments that mention this clinical trial
Documents that mention this clinical trial
Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
https://doi.org/10.1007/s12288-022-01602-5
-
Funding
Funding for this research was provided by:
Alkem Laboratories Ltd.
- License Information
-
More Information
Article History
Received: 12 July 2022
Accepted: 18 October 2022
First Online: 15 November 2022
Change Date: 27 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12288-023-01635-4
Declarations
:
: None.
: Informed consent was obtained from all individual participants included in the study.
: The participant has consented to the submission of the case report to the journal.
: The study protocol was approved at all the institutional ethics committees.
